Vis enkel innførsel

dc.contributor.authorSerigstad, Sondre
dc.contributor.authorRitz, Christian
dc.contributor.authorFaurholt-Jepsen, Daniel
dc.contributor.authorMarkussen, Dagfinn Lunde
dc.contributor.authorEbbesen, Marit Helen
dc.contributor.authorKommedal, Øyvind
dc.contributor.authorBjørneklett, Rune Oskar
dc.contributor.authorHeggelund, Lars
dc.contributor.authorClark, Tristan W.
dc.contributor.authorvan Werkhoven, Cornelis H.
dc.contributor.authorKnoop, Siri Tandberg
dc.contributor.authorUlvestad, Elling
dc.contributor.authorGrewal, Harleen
dc.date.accessioned2022-11-30T08:43:30Z
dc.date.available2022-11-30T08:43:30Z
dc.date.created2022-10-20T15:08:53Z
dc.date.issued2022
dc.identifier.issn1745-6215
dc.identifier.urihttps://hdl.handle.net/11250/3034905
dc.description.abstractBackground: Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Methods: Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l’Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. Discussion: We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleImpact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 the authorsen_US
dc.source.articlenumber622en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s13063-022-06467-7
dc.identifier.cristin2063343
dc.source.journalTrialsen_US
dc.identifier.citationTrials. 2022, 23, 622.en_US
dc.source.volume23en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal